• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.

作者信息

Goletti Delia, Cantini Fabrizio

机构信息

From the Translational Research Unit, Department of Epidemiology and Preclinical Research, L. Spallanzani-IRCCS National Institute for Infectious Diseases, Rome (D.G.), and the Rheumatology Department, Azienda Unità Sanitaria Locale Toscana Centro, Hospital of Prato, Prato (F.C.) - both in Italy.

出版信息

N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.

DOI:10.1056/NEJMe2034982
PMID:33657299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7944951/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0293/7944951/452d3c376c39/NEJMe2034982_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0293/7944951/452d3c376c39/NEJMe2034982_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0293/7944951/452d3c376c39/NEJMe2034982_f1.jpg

相似文献

1
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.巴瑞替尼治疗新冠病毒肺炎——满足一项未被满足的需求
N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.
2
Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.瑞德西韦或瑞德西韦联合巴利昔替尼治疗中重度 COVID-19 肺炎患者的死亡率比较：一项回顾性研究。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
3
Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.巴瑞替尼/瑞德西韦治疗成人 COVID-19 感染的关联观点。
Mol Biol Rep. 2022 Jan;49(1):827-831. doi: 10.1007/s11033-021-06888-8. Epub 2021 Nov 27.
4
In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.在因 COVID-19 住院的成年人中，与地塞米松相比，将巴瑞替尼加用至瑞德西韦并未改善有创机械通气生存。
Ann Intern Med. 2022 Oct;175(10):JC115. doi: 10.7326/J22-0074. Epub 2022 Oct 4.
5
Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.巴瑞替尼、瑞德西韦和地塞米松联合治疗 COVID-19 缺氧成人患者的疗效：一项回顾性研究。
Respir Med Res. 2022 May;81:100903. doi: 10.1016/j.resmer.2022.100903. Epub 2022 Mar 19.
6
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.巴瑞替尼、瑞德西韦和地塞米松联合治疗重症 COVID-19 患者的临床影响。
Respir Investig. 2021 Nov;59(6):799-803. doi: 10.1016/j.resinv.2021.07.004. Epub 2021 Aug 10.
7
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性（COV-BARRIER）：一项随机、双盲、平行分组、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1.
8
An EUA for baricitinib (Olumiant) for COVID-19.巴瑞替尼（Olumiant）用于治疗新冠肺炎的紧急使用授权。
Med Lett Drugs Ther. 2020 Dec 28;62(1614):202-203.
9
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.巴瑞替尼/瑞德西韦/重组人血管紧张素转化酶 2 三联药物疗法治疗 COVID-19 感染的关联和药理学协同作用。
Naunyn Schmiedebergs Arch Pharmacol. 2022 Jan;395(1):99-104. doi: 10.1007/s00210-021-02169-0. Epub 2021 Oct 20.
10
The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.心血管临床试验专家的第11次试验：冠状病毒-2：第5部分。
Cardiol Rev. 2021;29(3):109. doi: 10.1097/CRD.0000000000000386.

引用本文的文献

1
Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.半胱胺的免疫调节作用及其作为结核病宿主导向治疗的潜在用途。
Front Immunol. 2024 Oct 28;15:1411827. doi: 10.3389/fimmu.2024.1411827. eCollection 2024.
2
Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19.对肺部蛋白质组的纵向分析揭示了轻度至中度新冠肺炎数月后持续的修复情况。
Cell Rep Med. 2024 Jul 16;5(7):101642. doi: 10.1016/j.xcrm.2024.101642. Epub 2024 Jul 8.
3
Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval.

本文引用的文献

1
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
2
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.JAK 抑制可降低 SARS-CoV-2 的肝脏感染性，并调节炎症反应，从而降低发病率和死亡率。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe4724. Print 2021 Jan.
3
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.
《COVID-19 治疗药物的作用机制综述：从发现到批准》。
J Korean Med Sci. 2024 Apr 15;39(14):e134. doi: 10.3346/jkms.2024.39.e134.
4
Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey.分析 SARS-CoV-2 感染后 RA 发作的相关因素：一项来自患者调查的回顾性研究。
Sci Rep. 2024 Feb 20;14(1):4243. doi: 10.1038/s41598-024-52748-3.
5
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.COVID-19 患者中 JAK1/2 抑制剂芦可替尼引发的过度炎症：RuxCoFlam 试验。
Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28.
6
The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions.IL-10 的多效性：调节、在免疫稳态中的作用及其与癌症、COVID-19 和新冠后状况的相关性。
Front Immunol. 2023 Jun 8;14:1161067. doi: 10.3389/fimmu.2023.1161067. eCollection 2023.
7
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study.瑞德西韦和中和单克隆抗体单药或联合治疗对降低 COVID-19 住院老年或免疫功能低下宿主疾病进展风险的疗效：一项单中心回顾性研究。
Viruses. 2023 May 19;15(5):1199. doi: 10.3390/v15051199.
8
Impact of Vaccination on Cost and Course of Hospitalization Associated with COVID-19 Infection.疫苗接种对与新冠病毒感染相关的住院费用及病程的影响。
Antimicrob Steward Healthc Epidemiol. 2023 Jan 25;3(1):e19. doi: 10.1017/ash.2022.364. eCollection 2023.
9
[Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients.托珠单抗治疗 COVID-19 患者的疗效和边际成本。
Farm Hosp. 2023 Jan-Feb;47(1):T10-T15. doi: 10.1016/j.farma.2022.12.014. Epub 2022 Dec 28.
10
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia.用于治疗新冠病毒肺炎的Janus激酶抑制剂综述
Inflamm Regen. 2023 Jan 9;43(1):3. doi: 10.1186/s41232-022-00253-3.
地塞米松用于住院的COVID-19患者：解决不确定性问题。
Lancet Respir Med. 2020 Dec;8(12):1170-1172. doi: 10.1016/S2213-2600(20)30503-8. Epub 2020 Oct 29.
4
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.免疫疗法，或抗病毒疗法，或两者联合用于治疗 COVID-19：系统评价。
Drugs. 2020 Dec;80(18):1929-1946. doi: 10.1007/s40265-020-01421-w.
5
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities.意大利 COVID-19 患者的尸检结果：有和无合并症病例的描述性全面尸检研究。
J Infect Dis. 2020 Nov 9;222(11):1807-1815. doi: 10.1093/infdis/jiaa578.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.巴瑞替尼对 COVID-19 中度肺炎的有益影响；多中心研究。
J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.
8
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
9
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.巴瑞替尼治疗新冠肺炎：一项关于安全性和临床影响的初步研究。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.
10
Mild or Moderate Covid-19.轻度或中度新冠病毒感染
N Engl J Med. 2020 Oct 29;383(18):1757-1766. doi: 10.1056/NEJMcp2009249. Epub 2020 Apr 24.